Mild acne is one of the most common dermatological conditions, particularly among adolescents and young adults. Despite its generally favorable course, even mild forms of acne can significantly reduce patients’ quality of life and require timely and effective treatment. Azelaic acid, included in modern topical formulations, has well-documented comedolytic, anti-inflammatory, and bacteriostatic properties, without contributing to microbial resistance. This makes it an important component of acne therapy, especially in outpatient clinical settings. This paper presents a review of current approaches to the treatment of mild acne, with a focus on the clinical potential of azelaic acid. In addition, the authors describe clinical experience with the topical medication Skinoclear, available in cream form with a 20% concentration and gel form with a 15% concentration. The product was used in outpatient practice, with photographic documentation of the skin condition before and after treatment. All patients showed a reduction in both inflammatory and non-inflammatory lesions within 4 to 8 weeks. The treatment was well tolerated, with no reported significant adverse reactions or treatment discontinuations. Thus, azelaic acid as part of the Skinoclear formulation demonstrates good clinical efficacy and tolerability, supporting its role as a treatment of choice in the management of mild acne. © 2025 Elsevier B.V., All rights reserved.